NEW YORK, March 26, 2020 /PRNewswire/ -- AIkido Pharma
Incorporated (Nasdaq: AIKI) today provided an update onto
shareholders as follows:
Dear Fellow Shareholder,
AIkido Pharma is financially secure. We raised sufficient
capital to both survive and potentially thrive during the turbulent
times brought about by the COVID-19 virus. In fact, we are in
a position to acquire additional assets moving forward and we are
investigating other opportunities. When this crisis passes,
which it will, it is my goal for AIkido to be stronger and more
diversified than when the crisis started.
We have received many questions about the COVID-19 option
previously announced. As we said in our March 18, 2020 press release, we are actively
investigating the technology. If the technology is viable,
and reasonable licensing terms that inure to the benefit of our
shareholders can be negotiated, we will move forward with
development. But the converse is also true, and each
shareholder should understand that we may not secure a license on
the previously announced technology. There are several
research projects ongoing regarding potential treatments for
COVID-19, and each of these projects requires funding. We are
continuing to vet opportunities in this area. We remain
committed to keeping you informed and will provide information as
it comes available.
We have also received questions about the timing of the Hoth
stock dividend. We are anxious to deliver these shares to our
shareholders, but it's not the Company that is holding up the
distribution. We are working with Hoth and the appropriate
regulatory agencies to effectuate the transfer. As soon as we
are able, we will make this distribution. We are aware that
this has been a slow and potentially frustrating process. I
apologize for any frustration you are experiencing, and I assure
you that I am committed to delivering this dividend as soon as we
are able.
Finally, AIkido is being proactive in this time of crisis.
We accept the challenge issued to companies and we pledge to not
layoff any employees as a result of the current pandemic. For
the Company, this includes not laying off our contract
employees. We are further looking to see if we can reach out
and help our communities at this time of crisis. We have
begun discussions with other businesses to investigate avenues of
help, such as short-term hiring of newly unemployed workers, to
assist our fellow Americans. Whether you define this as a
moral duty, a civic duty, or just the right thing to do, we are
doing it. Again, our decisive and strategic decision to raise
capital at the start of the crisis, has put us in a position to
help those less fortunate, and to survive this crisis stronger than
when the crisis started.
I want to thank each of you for being a shareholder and we will
be providing more information about these issues as they become
available.
Sincerely,
Anthony Hayes
About AIkido
AIkido was initially formed in 1967 and is currently a
biotechnology company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-issues-shareholder-update-on-covid-19-dividend-and-path-forward-301030403.html
SOURCE AIkido Pharma Incorporated